Parallel Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD

Parallel Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 111.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 74,470 shares of the biopharmaceutical company’s stock after acquiring an additional 39,239 shares during the quarter. Parallel Advisors LLC’s holdings in Gilead Sciences were worth $8,266,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Corundum Trust Company INC purchased a new position in Gilead Sciences during the third quarter valued at approximately $26,000. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences in the second quarter worth $30,000. MTM Investment Management LLC raised its position in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the period. Kilter Group LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $33,000. Finally, Millstone Evans Group LLC lifted its stake in shares of Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 118 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Wolfe Research increased their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Scotiabank upped their price objective on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Finally, Daiwa Securities Group lifted their target price on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $156.72.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $144.08 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The business has a 50 day simple moving average of $138.29 and a two-hundred day simple moving average of $125.80. The stock has a market capitalization of $178.86 billion, a PE ratio of 21.28, a P/E/G ratio of 1.89 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s payout ratio is currently 46.68%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares in the company, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 309,280 shares of company stock worth $43,935,470 over the last three months. 0.27% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.